Leflon

Leflunomide, the active ingredient in Leflon, is a Disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients, where it helps reduce inflammation and slow disease progression.

GNH USA supplies Leflon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Leflon, a disease-modifying antirheumatic drug, is used to manage inflammatory arthritis conditions.

Rheumatoid arthritis: reduces joint inflammation and slows structural damage. Psoriatic arthritis: improves skin lesions and joint symptoms. Active inflammatory arthritis: provides disease‑modifying benefits when other DMARDs are insufficient.

Leflon may cause a range of adverse reactions.

Common Side Effects: - Diarrhoea - Nausea or abdominal discomfort - Alopecia (hair loss) - Rash or pruritus - Elevated liver enzymes - Hypertension

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Bone‑marrow suppression leading to cytopenias - Pulmonary toxicity (interstitial lung disease) - Serious infections due to immunosuppression - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Teratogenic effects causing fetal harm

Before initiating Leflon, several safety considerations should be observed.

Pregnancy: contraindicated (Category X); avoid use in pregnant women. Liver function: obtain baseline tests and monitor periodically. Blood counts: perform regular CBC monitoring for cytopenias. Infections: defer treatment in active infections and avoid live vaccines. Vaccinations: administer required vaccines before starting therapy. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Leflon can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect. - Methotrexate: additive bone‑marrow toxicity. - Azathioprine: heightened risk of cytopenias. - Live vaccines: risk of severe infection.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may raise leflunomide levels. - CYP1A2 inducers (e.g., smoking): may reduce efficacy. - NSAIDs: increased gastrointestinal bleeding risk.